Russell Schundler, General Counsel of Liquidia Corp (NASDAQ:LQDA), sold 14,738 shares of the company’s common stock for a total value of $1,053,925. The transactions occurred on July 13, 2026, with prices ranging from $71.39 to $71.52 per share. These sales were executed pursuant to a Rule 10b5-1 plan, which Mr. Schundler adopted on December 15, 2023, and were primarily conducted to cover taxes associated with the settlement of restricted stock units (RSUs) and performance stock units (PSUs). The stock has since climbed to $76.47, reflecting a remarkable 427% return over the past year.
Prior to these sales, on July 10, 2026, Mr. Schundler acquired a total of 10,168 shares of common stock. These shares were obtained through the conversion of performance stock units (PSUs), which convert into common stock on a one-for-one basis. The PSUs included 3,759 units granted on January 11, 2024, and 6,409 units granted on January 11, 2025, that had vested as of the report date. Liquidia’s strong fundamentals include an impressive gross profit margin of 92% and profitability over the last twelve months. According to InvestingPro analysis, the stock appears undervalued at current levels, with 18 additional ProTips available to subscribers.
Following these transactions, Mr. Schundler directly holds 605,962 shares of Liquidia Corp common stock. This total includes 13,021 unvested RSUs from a January 2023 grant, 41,300 unvested RSUs from a January 2024 grant, 64,089 unvested RSUs from a January 2025 grant, 32,955 unvested RSUs from a January 2026 grant, and 12,306 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Additionally, Mr. Schundler indirectly holds 14,500 shares through his spouse, though he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
In other recent news, Liquidia Corporation has reported several notable developments. Firstly, BofA Securities downgraded Liquidia’s stock rating from Buy to Neutral, although it raised the price target from $64 to $79. This decision comes after the company’s drug, Yutrepia, surpassed sales expectations, leading BofA to increase its peak sales estimate to $2.2 billion. Additionally, H.C. Wainwright raised its price target for Liquidia to $75, maintaining a Buy rating, due to favorable legal outcomes related to a Supreme Court ruling. Similarly, Raymond James reiterated a Strong Buy rating with a price target of $68, also citing positive implications from the same legal decision.
In another development, Liquidia is set to join the S&P SmallCap 600 Index, effective June 22. This inclusion reflects the company’s market capitalization, liquidity, and profitability metrics. The S&P SmallCap 600 Index tracks 600 small-cap U.S. companies based on specific criteria. These recent updates highlight significant shifts in Liquidia’s market positioning and investor outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News
